Tong Shizheng, Zhao Wei, Zhao Duoyi, Zhang Weilin, Zhang Zhiyu
Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Front Bioeng Biotechnol. 2022 Jun 9;10:916926. doi: 10.3389/fbioe.2022.916926. eCollection 2022.
Agents for tumor vascular infarction are recently developed therapeutic agents for the vascular destruction of tumors. They can suppress the progression of the tumor by preventing the flow of nutrition and oxygen to its tissues. Agents of tumor vascular infarction can be divided into three categories according to the differences in their pathways of action: those that use the thrombin-activating pathway, fibrin-activating pathway, and platelet-activating pathway. However, poor targeting ability, low permeation, and potential side-effects restrict the development of the corresponding drugs. Biomaterials can subtly avoid these drawbacks to suppress the tumor. In this article, the authors summarize currently used biomaterials for tumor infarction therapy with the goal of identifying its mechanism, and discuss outstanding deficiencies in methods of this kind.
肿瘤血管梗塞剂是最近开发的用于肿瘤血管破坏的治疗剂。它们可以通过阻止营养物质和氧气流向肿瘤组织来抑制肿瘤的进展。根据作用途径的不同,肿瘤血管梗塞剂可分为三类:使用凝血酶激活途径、纤维蛋白激活途径和血小板激活途径的药物。然而,靶向能力差、渗透性低和潜在的副作用限制了相应药物的开发。生物材料可以巧妙地避免这些缺点来抑制肿瘤。在本文中,作者总结了目前用于肿瘤梗塞治疗的生物材料,目的是确定其作用机制,并讨论这类方法存在的突出不足。